Table 1 Baseline characteristics, type of preceding surgery and anticoagulation/platelet inhibition

Number of patients

86

22

64

Age (years)

67.3 ± 7.4

65.9 ± 7.9

67.8 ± 7.3

0.315

Sex, n (%)

0.575

 Male

66 (76.7)

16 (72.7)

50 (78.1)

 Female

20 (23.3)

6 (27.3)

14 (21.9)

ASA class, n (%)

0.75

 ASA III

71 (82.6)

19 (86.4)

52 (81.3)

 ASA IV

15 (17.4)

3 (13.6)

12 (18.7)

NYHA class

0.485

 NYHA 1

3 (3.8)

1 (5.0)

2 (3.4)

 NYHA 2

26 (32.9)

5 (25.0)

21 (35.6)

 NYHA 3

46 (58.2)

14 (70.0)

32 (54.2)

 NYHA 4

4 (5.1)

—

4 (6.8)

Diabetes mellitus, n (%)

54 (62.8)

13 (59.1)

41 (64.1)

0.799

 On insulin, n (%)

25 (29.1)

7 (31.8)

18 (28.1)

0.789

Atrial fibrillation, n (%)

31 (36.0)

8 (36.4)

23 (35.9)

1

COPD, n (%)

17 (19.8)

3 (13.6)

14 (21.9)

0.541

BMI¹

0.629

 Non-obese, n (%)

47 (54.7)

11 (50.0)

36 (56.3)

 Obese, n (%)

39 (45.3)

11 (50.0)

28 (43.8)

Platelet inhibitor, n (%)

0.901

 None

12 (14.0)

3 (13.6)

9 (14.1)

 Singe

68 (79.1)

17 (77.3)

51 (79.7)

 Double

6 (7.0)

2 (9.1)

4 (6.3)

Therap. heparine, n (%)

52 (60.5)

16 (72.7)

36 (56.3)

0.212

preceding cardiac surgery

 CABG

43 (50.0)

18 (81.8)

25 (39.1)

0.001

 LIMA²

61 (70.9)

15 (68.2)

46 (71.9)

0.789

 Valve

11 (45.3)

2 (9.1)

9 (14.6)

0.721

 CABG + Valve

23 (26.7)

—

23 (35.9)

0.0001

 Aortic

8 (9.3)

2 (9.1)

6 (9.4)

1

 Non-cardiac³

1 (1.1)

–

1

–